Longitudinal systolic dysfunction in hypertensive cardiomyopathy with normal ejection fraction - DocWire News

This article was originally published here

Echocardiography. 2021 Dec 13. doi: 10.1111/echo.15267. Online ahead of print.

ABSTRACT

BACKGROUND: The left ventricle (LV) journey in their transition from hypertrophy to heart failure is marked by many subcellular events partially understood yet. The moment in which the structural abnormalities reach the umbral to induce myocardial dysfunction remains elusive.

AIMS: To evaluate the anatomic-functional relationship between LV wall thickness and longitudinal systolic dysfunction.

MATERIAL AND METHODS: We prospectively performed clinical assessment and transthoracic echocardiogram on healthy individuals and hypertensive patients with left ventricle ejection fraction (LVEF) ≥50% and absence of heart failure symptoms.

RESULTS: A total of 226 patients and 101 healthy individuals were recruited. The distribution for sex was similar between groups. The mean age was 67±13 years old in the patients, and 44% had concentric LV hypertrophy. LVEF was identical in both groups (63±6%); in contrast, global longitudinal strain (GLS) (-18.8±2.5% vs -20.4±2%) and mitral annulus plane systolic excursion (MAPSE) (13.8±2.8 vs 15.5±2 mm) were lower. ROC curve optimally classified decreased GLS with LV septum thickness ≥13 mm and decreased MAPSE with thickness ≥14 mm. Multivariable logistic regression found that LV septum thickness is the only variable associated with longitudinal systolic dysfunction (OR = 1.1, CI95% = 1.05 – 1.15, P = 0.001, R squared = .38).

DISCUSSION: A progressive increase in LV wall thickness due to myocyte hypertrophy and interstitial expansion is associated with LV systolic longitudinal dysfunction.

CONCLUSIONS: Patients with moderate or severe ventricular hypertrophy (septum ≥13 mm) had longitudinal systolic dysfunction, GLS decreases with minor structural change than MAPSE, and LVEF is insensitive in detecting longitudinal myocardial dysfunction in patients with hypertension.

PMID:34904277 | DOI:10.1111/echo.15267

Comments

Post a Comment

Popular posts from this blog

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor

Image
Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Posted: 11 Jul 2019 12:00 AM PDT For patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction, inhaled epoprostenol through high-flow nasal cannula increases oxygenation, according to a study published in Pharmaceutics . The researchers of this retrospective study assessed the effect of inhaled epoprostenol using a high-flow nasal cannula on oxygenation and future mechanical ventilation in patients with hypoxemia comorbid with pulmonary hypertension or right heart dysfunction in an intensive care unit setting. A chart review was completed on adult patients who were admitted into the respiratory care department of the Rush University Medical Center for severe hypoxemia between July 2015 and April 2018 and treated with inha...
Read more

Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News

Image
Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Growing Doubt, Uncertainty Over PDE5i Use in Left Heart Disease - Medscape AnMed Health gains national recognition through the Pulmonary Hypertension Association - WSPA.com Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Posted: 12 Jun 2019 05:00 AM PDT The U.S. Food and Drug Administration (FDA) has approved Novitium Pharma 's generic sildenafil for oral suspension at a dose of 10 mg/mL for the treatment of pulmonary arterial hypertension (PAH). This product, which had been designated a competitive generic therapy by the FDA, is the first approved generic equivalent to Pfizer 's Revatio , a vasodilator agent that induces blood ves...
Read more

Analysis: Large pharma companies do little new drug innovation - STAT

Image
Analysis: Large pharma companies do little new drug innovation - STAT Analysis: Large pharma companies do little new drug innovation - STAT Gene Therapy Takes Center Stage at 2019 NORD Summit - Pulmonary Hypertension News People Living With Type 2 Diabetes Want Information and Empathy From Their Doctors More Than New Medications - PRNewswire Analysis: Large pharma companies do little new drug innovation - STAT Posted: 10 Dec 2019 01:51 AM PST L arge pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug development and the discovery of new medicines, and thus lead to a decline in drug innovation. If that argument is credible, there should be evidence to show that the large pharmaceutical companies are responsible for discovering innovative new drugs. To test that claim, we examined the...
Read more